Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Philippe Lechat

Showing results (51-60 of 110) with videos related to

Pageof 11
Sort By:
Therapeutic Drug Monitoring|May 29, 2004
Effect of renal function on the pharmacokinetics of enoxaparin and consequences on dose adjustmentJean-Sébastien Hulot, Clarisse Vantelon, Saïk Urien, et al.
Biological Psychiatry|June 21, 2008
Epilepsy in autism is associated with intellectual disability and gender: evidence from a meta-analysisClaire Amiet, Isabelle Gourfinkel-An, Anissa Bouzamondo, et al.
Nephrologie & Therapeutique|August 10, 2006
[Tubular transporters OAT1 and MRP2 and clearance of adefovir]Aude Servais, Philippe Lechat, Noël Zahr, et al.
Fundamental & Clinical Pharmacology|May 5, 2006
Use of an indirect effect model to describe the LDL cholesterol-lowering effect by statins in hypercholesterolaemic patientsDemiana William Faltaos, Saïk Urien, Valérie Carreau, et al.
Arthritis and Rheumatism|February 5, 2005
Corrected QT interval in anti-SSA-positive adults with connective tissue disease: comment on the article by Lazzerini et alNathalie Costedoat-Chalumeau, Zahir Amoura, Jean-Sébastien Hulot, et al.
European Journal of Pharmacology|June 8, 2006
Tubular transporters and clearance of adefovirAude Servais, Philippe Lechat, Noël Zahr, et al.
Annals of the Rheumatic Diseases|February 28, 2007
Very low blood hydroxychloroquine concentration as an objective marker of poor adherence to treatment of systemic lupus erythematosusNathalie Costedoat-Chalumeau, Zahir Amoura, Jean-Sébastien Hulot, et al.
Pharmacology & Toxicology|June 6, 2003
Comparative pharmacokinetics and pharmacodynamics of intravenous and oral nefopam in healthy volunteersGuy Aymard, Dominique Warot, Pierre Démolis, et al.
Clinical Pharmacokinetics|March 14, 2008
Pharmacokinetic study of mycophenolate mofetil in patients with systemic lupus erythematosus and design of Bayesian estimator using limited sampling strategiesNoël Zahr, Zahir Amoura, Jean Debord, et al.
European Journal of Heart Failure|August 6, 2010
Congestion in chronic systolic heart failure is related to renal dysfunction and increased mortalityKevin Damman, Adriaan A Voors, Hans L Hillege, et al.
Pageof 11

Showing results (51-60 of 110) with videos related to

Sort By:
Pageof 11
Therapeutic Drug Monitoring|May 29, 2004
Effect of renal function on the pharmacokinetics of enoxaparin and consequences on dose adjustmentJean-Sébastien Hulot, Clarisse Vantelon, Saïk Urien, et al.
Biological Psychiatry|June 21, 2008
Epilepsy in autism is associated with intellectual disability and gender: evidence from a meta-analysisClaire Amiet, Isabelle Gourfinkel-An, Anissa Bouzamondo, et al.
Nephrologie & Therapeutique|August 10, 2006
[Tubular transporters OAT1 and MRP2 and clearance of adefovir]Aude Servais, Philippe Lechat, Noël Zahr, et al.
Fundamental & Clinical Pharmacology|May 5, 2006
Use of an indirect effect model to describe the LDL cholesterol-lowering effect by statins in hypercholesterolaemic patientsDemiana William Faltaos, Saïk Urien, Valérie Carreau, et al.
Arthritis and Rheumatism|February 5, 2005
Corrected QT interval in anti-SSA-positive adults with connective tissue disease: comment on the article by Lazzerini et alNathalie Costedoat-Chalumeau, Zahir Amoura, Jean-Sébastien Hulot, et al.
European Journal of Pharmacology|June 8, 2006
Tubular transporters and clearance of adefovirAude Servais, Philippe Lechat, Noël Zahr, et al.
Annals of the Rheumatic Diseases|February 28, 2007
Very low blood hydroxychloroquine concentration as an objective marker of poor adherence to treatment of systemic lupus erythematosusNathalie Costedoat-Chalumeau, Zahir Amoura, Jean-Sébastien Hulot, et al.
Pharmacology & Toxicology|June 6, 2003
Comparative pharmacokinetics and pharmacodynamics of intravenous and oral nefopam in healthy volunteersGuy Aymard, Dominique Warot, Pierre Démolis, et al.
Clinical Pharmacokinetics|March 14, 2008
Pharmacokinetic study of mycophenolate mofetil in patients with systemic lupus erythematosus and design of Bayesian estimator using limited sampling strategiesNoël Zahr, Zahir Amoura, Jean Debord, et al.
European Journal of Heart Failure|August 6, 2010
Congestion in chronic systolic heart failure is related to renal dysfunction and increased mortalityKevin Damman, Adriaan A Voors, Hans L Hillege, et al.
Pageof 11